Tellez, Ronald Sergio LimónReynolds, LuciaPiris, Miguel A2026-03-242026-03-2420231754-6605PMID:3739609810.3332/ecancer.2023.1556https://doi.org/10.3332/ecancer.2023.1556https://andeanlibrary.org/handle/123456789/100930Vol. 17, pp. 1556Recent advances in cancer treatment such as PD-1/PD-L1 checkpoint inhibitors have prompted multiple research studies to determine all of the factors that influence response or failure to these new treatments. One of those identified factors is myeloid-derived suppressor cells (MDSCs). These cells were identified and described for the first time in 2007 in laboratory mice and cancer patients. Previous studies showed that a greater number of MDSCs was directly related to a greater tumour volume. There are two clearly identified subpopulations: Mononuclear-type myeloid-derived suppressor cells (M-MDSCs) and polymorphonuclear (PMN-MDSCs). These cell population subtypes play a very important role, depending on the type of cancer, since they have the particularity of expressing PD-L1, which interacts with PD-1, inhibiting the expansion of cytotoxic T lymphocytes, promoting resistance to these treatments.engMyeloid-derived suppressor cells (MDSCs)PD-1 and PD-L1immunotherapytumour microenvironmentArtículo Científico Publicado